Author + information
- Huseyin Altug Cakmak1,
- Hasan Ali Barman1,
- Ender Coskunpinar2,
- Yasemin Musteri Oltulu2,
- Baris Ikitimur1,
- Gunay Can3 and
- Vural Ali Vural1
MicroRNAs (miRNAs) are small, endogenous and non-coding RNAs that are 21-25 nucleotides in length. Recent studies have demonstrated the role of miRNAs as potential biomarkers in various disorders. The aim of this study was to quantitatively evaluate expression levels of miRNAs with functional differences in patient with congestive heart failure (CHF).
In our study, 20 clinically stable (NYHA II) and 22 decompansated (NYHA III and IV) systolic CHF (EF <%40) patients and 15 healthy controls were enrolled. Whole genome miRNA profiling was done and dysregulated miRNAs were detected with microarray method in CHF patients compared to healthy controls.
Microarray profiling showed serum miR-21, miR-4278, miR-650, miR-744star, miR-516-5p, miR-1292, miR-182, miR-1228, miR-595, miR-663b, miR-1296, miR-1825, miR-299-3p, miR-662 miR-122-star, miR-3148, miR-518e-star, miR-2054 as up regulated, and serum miR-129-3p, miR-3155, miR-3175, miR-583, miR-568, miR-30d, miR-200a-star, miR-1979, miR-371-3p, miR-155-star, miR-502-5p as down regulated in CHF patients with a significant increase of >1.2 fold (p<0.05) (Figure). There was no association between these miRNAs and important clinical prognostic parameters such as NYHA class (p>0.05), pro-BNP (p>0.05) and high sensitive C-reactive protein (hs-CRP) (p>0.05).
The present study indicated that patients with heart failure exhibit different serum miRNA profile compared to healthy controls.